期刊文献+

扶正抑瘤方对晚期非小细胞肺癌化疗增效减毒作用及TSGF的影响 被引量:5

Effects of “Fuzheng Yiliu Decoction” on Chemotherapeutic Reactions and TSGF of Advanced Non-small Cell Lung Cancer
下载PDF
导出
摘要 目的观察扶正抑瘤方对晚期非小细胞肺癌化疗毒副反应的减毒作用及其对肿瘤特异性生长因子(TSGF)水平的影响。方法将42例患者随机分为对照组(20例,采用单纯化疗治疗)和综合组(22例,化疗结合扶正抑瘤方治疗),21d为1个周期,两组均连续治疗2个周期。比较两组患者化疗通过率,毒副反应,生活质量,血清TSGF水平。结果综合组化疗通过率略高于化疗组,生活质量明显高于化疗组,化疗毒副反应小于化疗组,TSGF下降水平大于化疗组。结论自拟扶正抑瘤方能够改善晚期肺癌患者生活质量,能在一定程度上降低化疗的毒副反应,并协同化疗起到抑瘤的作用。 To observe the clinical effects of "Fuzheng Yiliu Decoction" on non-small cell lung cancer and TSGF. Methods Forty-two subjects were randomized into two groups: control group in which 20 cases were treated simply by chemotherapy and treatment group in which 22 cases were treated with chemotherapy plus "Fuzheng Yiliu Decoction", with two courses. The chemotherapeutic effects, adverse reactions, quality of life and TSGF were observed. Results More patients in treatment group could endure chemotherapy; the quality of life was better, adverse reactions less and TSGF lower in treatment group than in control group. Conclusion "Fuzheng Yiliu Decoction" can improve the quality of life and relive adverse reactions in patients with advanced non-small cell lung cancer.
出处 《上海中医药杂志》 北大核心 2007年第6期18-19,共2页 Shanghai Journal of Traditional Chinese Medicine
关键词 扶正抑瘤方 晚期非小细胞肺癌 肺瘤特异性生长因子 化疗 "Fuzheng Yiliu Decoction" non-small cell lung cancer TSGF chemotherapy
  • 相关文献

参考文献4

二级参考文献10

  • 1徐元斌 王德春 等.恶性肿瘤特异性生长因子(TSGF)测定及临床应用[J].福建医学检验,1996,1(3):118-118. 被引量:90
  • 2汪欣 赵素萍.TSGF在肿瘤筛查中的意义[J].福建医学检验,1997,2(1):10-10. 被引量:45
  • 3刘嘉湘.实用中医肿瘤手册[M].上海:上海科技教育出版社,1998.103. 被引量:1
  • 4Paul A, Bunn J. Triplit chemotherapy with gemcitabin, a platinum and third agent in the treatment of advanced non-small cell lung .cancer[J].J Semin Oncol, 1999,26(1):25-30. 被引量:1
  • 5Sendler A, Michael J, David A, et al. Phase Ⅲ trial of gemeitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non small cell lung cancer [J]. J Clin Oncol, 2000, 18: 122-130. 被引量:1
  • 6Nevmark N, Lianes P, Smit EF, et al. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer[J].Pharmacoeconomics, 2005,23(11):1155-1166. 被引量:1
  • 7Kim JH,Kim SY,Jung KH,et al.Randomized phase Ⅱ study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer.Korean Cancer Study Group experience[J].Lung Cancer,2006,52(1):75-81. 被引量:1
  • 8Moscetti L,Nelli F, Padalino D, et al. Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer, impact of comorbidities on safety and efficacy outcome[J]. J Chemother, 2005,17(6):685-692. 被引量:1
  • 9Metsuyama K, Chiba Y, Sasaki M, et al. Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer[J]. Ann Thorac Surg, 1998, 65:1405-1409. 被引量:1
  • 10朱波,黄定瑞,黄文成.良恶性肿瘤患者血清恶性肿瘤特异性生长因子检测结果分析[J].广西医学,1999,21(4):617-621. 被引量:14

共引文献42

同被引文献59

引证文献5

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部